Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 6/20 | 0.54 |
| ▸ | IGF1R | P08069 | 6/20 | 0.54 |
| ▸ | KDR | P35968 | 5/20 | 0.54 |
| ▸ | INSR | P06213 | 1/20 | 0.47 |
| ▸ | FGFR2 | P21802 | 7/20 | 0.44 |
| ▸ | NOS1 | P29475 | 6/20 | 0.41 |
| ▸ | NOS2 | P35228 | 6/20 | 0.41 |
| ▸ | NOS3 | P29474 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3976688 | 0.87 | NOS2 (0.42) | FGFR1IGF1RKDRNOS1NOS2 | |
| SCHEMBL4086501 | 0.86 | FGFR1 (0.65) | FGFR1IGF1RKDRINSRFGFR2 | |
| SCHEMBL3940505 | 0.86 | FGFR1 (0.55) | FGFR1IGF1RKDRINSRFGFR2 | |
| SCHEMBL4010944 | 0.85 | FGFR1 (0.57) | FGFR1IGF1RKDRINSRFGFR2 | |
| SCHEMBL5103566 | 0.83 | FGFR1 (0.59) | FGFR1IGF1RKDRINSRFGFR2 | |
| SCHEMBL4010728 | 0.80 | FGFR1 (0.44) | FGFR1IGF1RKDRINSRFGFR2 | |
| SCHEMBL4012227 | 0.80 | FGFR1 (0.60) | FGFR1IGF1RKDRINSRFGFR2 | |
| SCHEMBL3852107 | 0.77 | ITK (0.45) | FGFR1IGF1RKDR | |
| SCHEMBL4011783 | 0.77 | FGFR1 (0.58) | FGFR1IGF1RKDRINSRFGFR2 | |
| SCHEMBL4011622 | 0.76 | IGF1R (0.49) | FGFR1IGF1RKDRINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009056886-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF FGFR ACTIVITY | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | WO | disclosed |